High-Consequence Infectious Diseases (HCIDs)

 

Guidance for High-Consequence Infectious Diseases

When handing specimens from patients with suspected high-consequence infectious diseases (HCIDs), such as Ebola Bundibugyo virus and Andes hantavirus, following accurate and up-to-date industry guidance is critical to patient and workforce safety.

Diagnostic Testing

• ARUP does not offer diagnostic testing for Ebola virus or hantavirus. 
• To facilitate efficient diagnostic testing, please work with your local health department for assistance.

Ancillary Testing

• Do not send specimens from patients with suspected HCIDs to ARUP for ancillary testing.
• To minimize exposure risks, please work with your local health department for assistance.

Refer to these resources for the most recent guidance from the CDC:

• Hantavirus: 2026 Hantavirus Outbreak: Testing for Potential Infection
• Ebola: Interim Guidance: Public Health Assessment and Management of Travelers Arriving From the Affected Countries During the 2026 Ebola Outbreak